Patents Assigned to XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
  • Patent number: 11857572
    Abstract: A method for increasing the proportion of a central memory T cell (Tcm) subset in a CAR-T cell product includes adding an artificial antigenic epitope in a CAR, and activating a CAR-T by the artificial antigenic epitope, wherein the artificial antigenic epitope does not exist in other domains or segments of the CAR. A method for preparing a CAR-T cell includes: introducing the CAR into a T cell; and culturing the CAR-introduced T cell, and performing specific activation in the culture process. The preparation method can not only increase the proportion of CAR-positive T cells in the product, but also can achieve specific in vitro amplification of the Tcm subset in the CAR-positive T cells, and significantly increases the proportion of Tcm in a final product. Clinical trials show that the CAR-T cells have significantly improved amplification capacity in vivo, and improved clinical safety and effectiveness.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: January 2, 2024
    Assignee: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Zhiguo Chen, Yu Zhao
  • Patent number: 11850429
    Abstract: The present invention relates to a multi-target electrical stimulation circuit, an electrical stimulator, and a signal output method of the electrical stimulator. The electrical stimulation circuit includes a control module, a plurality of brain wave acquisition modules and a plurality of stimulation adjustment modules. Each electrode is correspondingly provided with one brain wave acquisition module and one stimulation adjustment module, and different electrodes are used for stimulating different targets. The brain wave acquisition modules are used for acquiring brain wave signals in the corresponding electrodes and transmitting the brain wave signals to the control module. The control module is used for acquiring brain rhythm phase signals according to the received brain wave signals and outputting stimulation signals at preset waveform phase points after phase locking of the brain rhythm phase signals.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: December 26, 2023
    Assignee: Xuanwu Hospital Capital Medical University
    Inventors: Yuping Wang, Zhiyuan Yan
  • Publication number: 20230348591
    Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying specifically identifying DHYETDYTTGGESC in degradation fragments of an occludin protein, but not identify ing the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are significantly improved.
    Type: Application
    Filed: May 27, 2023
    Publication date: November 2, 2023
    Applicant: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Zhifeng QI, Kejian LIU, Xunming JI
  • Publication number: 20230312707
    Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying KTRRKMDRYDKSNIL in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are obviously improved.
    Type: Application
    Filed: May 26, 2023
    Publication date: October 5, 2023
    Applicant: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Xunming JI, Zhifeng QI, Kejian LIU
  • Patent number: 11737662
    Abstract: Disclosed is a visual imaging device based on PS-OCT for early demineralization and caries of dental hard tissues, comprising a laser light source for emitting a laser light, a coupler for receiving and dividing the laser light emitted by the laser light source into a reference laser light and a detection laser light; wherein the reference laser light backtracking to the coupler and the detection laser light backtracking to the coupler are coupled and then passed through a transmission grating and a convex lens to input as an optical signal into a linear CCD detector for converting the optical signal into an electrical signal which is then input to a computer control system and collected by a built-in capture card; and the computer is configured to perform a three-dimensional reconstruction of an image and perform two-dimensional cross-section image analysis; and the computer control system is connected to the scanning galvanometer to control a vibration of the scanning galvanometer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: August 29, 2023
    Assignee: XUANWU HOSPITAL, CAPITAL MEDICAL UNIVERSITY
    Inventors: Ying Zhao, Yuhao Bai
  • Patent number: 11351125
    Abstract: The invention relates to a poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system comprising the nanoparticle, and a method for preparing the nanoparticle or the drug delivery system. The nanoparticle is modified with a first modifier and a second modifier on the surface, the first modifier is a hydrophilic polymer, and the second modifier is an amino acid and/or a lipid. The invention further relates to a use of the nanoparticle in promoting drug penetration across the blood brain barrier in a subject.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 7, 2022
    Assignee: Xuanwu Hospital of Capital Medical University
    Inventors: Lan Zhang, Xiao Hu, Lin Li
  • Publication number: 20210369998
    Abstract: A cannula plugging device for rehabilitation after tracheotomy relates to the field of medical devices. The cannula plugging device includes a plugging device bracket. An outer wall of the plugging device bracket is fitted with a ring-shaped outer airbag. An inner wall of the plugging device bracket is fitted with a ring-shaped inner airbag. Two inflation tubes connecting the outer airbag and the inner airbag respectively are fitted on the plugging device bracket. The present invention makes the outer airbag and the inner wall of tracheotomy cannula pressed together by inflating the outer airbag. By gradually inflating the inner airbag and adjusting the size of the inner diameter of the lumen, the opening of the trachea gradually changes, so that the patient can gradually adapt to the process of plugging the cannula.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 2, 2021
    Applicants: Xuanwu Hospital Capital Medical University, Beijing Municipal Geriatric Medical Research Center
    Inventors: Junwei HAO, Haijie LIU, Xiyue ZHANG
  • Patent number: 11001639
    Abstract: Chimeric antigen receptors for efficient and selective in vitro proliferation and uses thereof. Specifically, the present invention provides a CAR-encoding molecule with specific selectivity in vitro. By introducing a humanized selective domain into the molecule, the CAR-positive cells after being infected can be efficiently sorted via a secondary sorting step. Upon exposure to the selective domain-specific antibody, the CAR-transduced immune cells can be selectively expanded; therefore, the ratio of the CAR-positive target cells in the final product is significantly increased, improving the efficiency of preparing CAR gene-modified immune cell products. The present invention provides a more reliable technical support for further promotion and application of such products in clinical practice.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: May 11, 2021
    Assignee: Xuanwu Hospital Capital Medical University
    Inventors: Zhiguo Chen, Yu Zhao
  • Publication number: 20210077531
    Abstract: A method for increasing the proportion of a central memory T cell (Tcm) subset in a CAR-T cell product includes adding an artificial antigenic epitope in a CAR, and activating a CAR-T by the artificial antigenic epitope, wherein the artificial antigenic epitope does not exist in other domains or segments of the CAR. A method for preparing a CAR-T cell includes: introducing the CAR into a T cell; and culturing the CAR-introduced T cell, and performing specific activation in the culture process. The preparation method can not only increase the proportion of CAR-positive T cells in the product, but also can achieve specific in vitro amplification of the Tcm subset in the CAR-positive T cells, and significantly increases the proportion of Tcm in a final product. Clinical trials show that the CAR-T cells have significantly improved amplification capacity in vivo, and improved clinical safety and effectiveness.
    Type: Application
    Filed: October 1, 2020
    Publication date: March 18, 2021
    Applicant: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Zhiguo CHEN, Yu ZHAO
  • Publication number: 20210017273
    Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying KTRRKMDRYDKSNIL in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are obviously improved.
    Type: Application
    Filed: June 21, 2020
    Publication date: January 21, 2021
    Applicant: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Xunming JI, Zhifeng QI, Kejian LIU
  • Publication number: 20200386773
    Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by only specifically identifying SKLSHIKKMVGDYDR in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are obviously improved.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 10, 2020
    Applicant: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: KeJian LIU, Xunming JI, Zhifeng QI
  • Publication number: 20200385462
    Abstract: A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying specifically identifying DHYETDYTTGGESC in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are significantly improved.
    Type: Application
    Filed: June 23, 2020
    Publication date: December 10, 2020
    Applicant: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Zhifeng QI, KeJian LIU, Xunming JI
  • Patent number: 10513512
    Abstract: The invention relates to flavanone derivatives, and preparation method and use thereof, particularly relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for preventing or treating a mental disorder or a nervous system disease. The compound of the invention exerts significant activity of inhibiting microglial activation and neuroinflammation, can antagonize dopamine D2 receptor, improve the ethological change in multiple animal models for mental disorders, effectively inhibit neuroinflammation and demyelination, and can be used to prevent or treat a mental disorder and a nervous system disease.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: December 24, 2019
    Assignee: Xuanwu Hospital of Capital Medical University
    Inventors: Lin Li, Hongshun Gu, Lan Zhang, Xi Chen, Linlin Yin, Ruyi Zhang, Cuicui Yang
  • Publication number: 20190117582
    Abstract: The invention relates to a poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system comprising the nanoparticle, and a method for preparing the nanoparticle or the drug delivery system. The nanoparticle is modified with a first modifier and a second modifier on the surface, the first modifier is a hydrophilic polymer, and the second modifier is an amino acid and/or a lipid. The invention further relates to a use of the nanoparticle in promoting drug penetration across the blood brain barrier in a subject.
    Type: Application
    Filed: February 21, 2017
    Publication date: April 25, 2019
    Applicant: Xuanwu Hospital of Capital Medical University
    Inventors: Lan Zhang, Xiao Hu, Lin Li
  • Publication number: 20190031644
    Abstract: The invention relates to flavanone derivatives, and preparation method and use thereof, particularly relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for preventing or treating a mental disorder or a nervous system disease. The compound of the invention exerts significant activity of inhibiting microglial activation and neuroinflammation, can antagonize dopamine D2 receptor, improve the ethological change in multiple animal models for mental disorders, effectively inhibit neuroinflammation and demyelination, and can be used to prevent or treat a mental disorder and a nervous system disease.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 31, 2019
    Applicant: Xuanwu Hospital of Capital Medical University
    Inventors: Lin LI, Hongshun GU, Lan ZHANG, Xi CHEN, Linlin YIN, Ruyi ZHANG, Cuicui YANG
  • Publication number: 20170069086
    Abstract: Embodiments of the present disclosure provide a method for constructing brain templates. First, thousands of brain MRI images are collected. Then, the collected brain MRI images are preprocessed and normalized to construct brain templates. Further, the constructed brain templates include brain templates corresponding to different age and gender groups and brain tissue probability maps corresponding to different age and gender groups. Therefore, embodiments of the present disclosure can construct brain templates by using the large sample size of brain MRI data, and support clinical applications and brain researches.
    Type: Application
    Filed: September 6, 2016
    Publication date: March 9, 2017
    Applicant: Xuanwu Hospital Capital Medical University
    Inventors: Kuncheng LI, Peipeng LIANG, Defeng WANG, Lin SHI
  • Patent number: 9233116
    Abstract: Composition containing iridoids such as morroniside and loganin, the use thereof in preparing medicaments for preventing and treating neurologic demyelinating diseases, and the method thereof in treating diseases related to neurologic demyelinating lesions are disclosed by the present application.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 12, 2016
    Assignee: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Lin Li, Linlin Yin, Lan Zhang, Wen Wang, Ruyi Zhang
  • Patent number: 9050353
    Abstract: New use of icariin and Epimedium flavaoids containing icariin is provided by the present invention.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: June 9, 2015
    Assignee: Xuanwu Hospital of Capital Medical University
    Inventors: Lin Li, Linlin Yin, Lili Lin, Lan Zhang, Wen Wang, Ruyi Zhang
  • Publication number: 20130157966
    Abstract: New use of icariin and Epimedium flavaoids containing icariin is provided by the present invention.
    Type: Application
    Filed: June 7, 2011
    Publication date: June 20, 2013
    Applicant: Xuanwu Hospital of Capital Medical University
    Inventors: Lin Li, Linlin Yin, Lili Lin, Lan Zhang, Wen Wang, Ruyi Zhang
  • Publication number: 20130116205
    Abstract: Composition containing iridoids such as morroniside and loganin, the use thereof in preparing medicaments for preventing and treating neurologic demyelinating diseases, and the method thereof in treating diseases related to neurologic demyelinating lesions are disclosed by the present application.
    Type: Application
    Filed: December 15, 2010
    Publication date: May 9, 2013
    Applicant: XUANWU HOSPITAL OF CAPITAL MEDICAL UNIVERSITY
    Inventors: Lin Li, Linlin Yin, Lan Zhang, Wen Wang, Ruyi Zhang